Literature DB >> 30222214

Metallacarboranes on the Road to Anticancer Therapies: Cellular Uptake, DNA Interaction, and Biological Evaluation of Cobaltabisdicarbollide [COSAN].

Isabel Fuentes1, Tania García-Mendiola2,3,4, Shinichi Sato5, Marcos Pita6, Hiroyuki Nakamura5, Encarnación Lorenzo2,3,4, Francesc Teixidor1, Fernanda Marques7, Clara Viñas1.   

Abstract

After uptake by U87 MG and A375 cancer cells, cobaltabisdicarbollide [COSAN]- distributes between membrane and nucleus and presents no relevant cytotoxicity against both cell lines even for long incubation times. The cytotoxicity of Na[COSAN] was also tested towards one normal cell line, the V79 fibroblasts, in order to ascertain the noncytotoxic profile of the compound. As the cell's nucleus contains DNA, the interaction between [COSAN]- and double-stranded calf thymus DNA (CT-dsDNA) has been investigated. There is a strong interaction between both molecules forming a nanohybrid CT-dsDNA-[COSAN] biomaterial, which was fully characterized. Moreover, Na[COSAN] shows characteristic redox peaks ascribed to the oxidation/reduction of Co3+/2+ at a formal potential of -1.444 V and it can be accumulated at a surface-immobilized DNA layer of glassy carbon electrodes. The equilibrium surface-binding constants (Kox /Kred ), which confirm that [COSAN]- interacts with DNA by an intercalative or electrostatic mode, depending on the ionic strength of the solution, were estimated. In addition, high binding affinity of Na[COSAN] to proteins was observed by 11 B{1 H} NMR and confirmed in vivo. Finally, biodistribution studies of [COSAN]- in normal mice were run. After administration, Na[COSAN] was distributed into many organs but mainly accumulated in the reticuloendothelial system (RES), including liver and spleen. After 1 h, the formation of aggregates by plasma protein interaction plays a role in the biodistribution profile; the aggregates accumulate mostly in the lungs. Na[COSAN], which displays low toxicity and high uptake by relevant cancer cells accumulating boron within the nucleus, could act as a suitable compound for further developments as boron neutron capture therapy (BNCT) agents.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  DNA recognition; antitumor agents; boron neutron capture therapy (BNCT); intercalations; metallacarboranes; redox chemistry

Mesh:

Substances:

Year:  2018        PMID: 30222214     DOI: 10.1002/chem.201803178

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  15 in total

1.  Light-Induced On/Off Switching of the Surfactant Character of the o-Cobaltabis(dicarbollide) Anion with No Covalent Bond Alteration.

Authors:  Abdelazim M A Abdelgawwad; Jewel Ann Maria Xavier; Daniel Roca-Sanjuán; Clara Viñas; Francesc Teixidor; Antonio Francés-Monerris
Journal:  Angew Chem Int Ed Engl       Date:  2021-10-26       Impact factor: 16.823

2.  Solid-State, Thermal Synthesis of Peptide/Protein-Boron Cluster Conjugates.

Authors:  Krzysztof Fink; Tomasz M Goszczyński
Journal:  Methods Mol Biol       Date:  2021

Review 3.  Preparing (Metalla)carboranes for Nanomedicine.

Authors:  Marta Gozzi; Benedikt Schwarze; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2021-03-19       Impact factor: 3.466

4.  Synthesis and study of C-substituted methylthio derivatives of cobalt bis(dicarbollide).

Authors:  Marina Yu Stogniy; Olga N Kazheva; Denis M Chudak; Gennady V Shilov; Oleg A Filippov; Igor B Sivaev; Andrey V Kravchenko; Vladimir A Starodub; Lev I Buravov; Vladimir I Bregadze; Oleg A Dyachenko
Journal:  RSC Adv       Date:  2020-01-16       Impact factor: 4.036

5.  Metallacarborane Complex Boosts the Rate of DNA Oligonucleotide Hydrolysis in the Reaction Catalyzed by Snake Venom Phosphodiesterase.

Authors:  Damian Kaniowski; Katarzyna Kulik; Katarzyna Ebenryter-Olbińska; Ewelina Wielgus; Zbigniew Leśnikowski; Barbara Nawrot
Journal:  Biomolecules       Date:  2020-05-05

Review 6.  Carboranes as unique pharmacophores in antitumor medicinal chemistry.

Authors:  Yu Chen; Fukuan Du; Liyao Tang; Jinrun Xu; Yueshui Zhao; Xu Wu; Mingxing Li; Jing Shen; Qinglian Wen; Chi Hin Cho; Zhangang Xiao
Journal:  Mol Ther Oncolytics       Date:  2022-01-10       Impact factor: 7.200

7.  Metallacarborane Derivatives Effective against Pseudomonas aeruginosa and Yersinia enterocolitica.

Authors:  Wieslaw Swietnicki; Waldemar Goldeman; Mateusz Psurski; Anna Nasulewicz-Goldeman; Anna Boguszewska-Czubara; Marek Drab; Jordan Sycz; Tomasz M Goszczyński
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

8.  Blue Emitting Star-Shaped and Octasilsesquioxane-Based Polyanions Bearing Boron Clusters. Photophysical and Thermal Properties.

Authors:  Justo Cabrera-González; Mahdi Chaari; Francesc Teixidor; Clara Viñas; Rosario Núñez
Journal:  Molecules       Date:  2020-03-07       Impact factor: 4.411

Review 9.  Boron neutron capture therapy: Current status and future perspectives.

Authors:  Mayya Alexandrovna Dymova; Sergey Yurjevich Taskaev; Vladimir Alexandrovich Richter; Elena Vladimirovna Kuligina
Journal:  Cancer Commun (Lond)       Date:  2020-08-17

10.  Cobaltabis(dicarbollide) ([o-COSAN]-) as Multifunctional Chemotherapeutics: A Prospective Application in Boron Neutron Capture Therapy (BNCT) for Glioblastoma.

Authors:  Miquel Nuez-Martinez; Catarina I G Pinto; Joana F Guerreiro; Filipa Mendes; Fernanda Marques; Amanda Muñoz-Juan; Jewel Ann Maria Xavier; Anna Laromaine; Valeria Bitonto; Nicoletta Protti; Simonetta Geninatti Crich; Francesc Teixidor; Clara Viñas
Journal:  Cancers (Basel)       Date:  2021-12-19       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.